{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T06:11:34Z","timestamp":1770531094961,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T00:00:00Z","timestamp":1400025600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s00277-014-2103-3","type":"journal-article","created":{"date-parts":[[2014,5,13]],"date-time":"2014-05-13T09:42:52Z","timestamp":1399974172000},"page":"1717-1724","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study"],"prefix":"10.1007","volume":"93","author":[{"given":"Mathias","family":"Witzens-Harig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Fo\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Di Rocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"van Hazel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalton F. A.","family":"Chamone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob M.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Arcaini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Poddubnaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrej","family":"Vranovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Thurley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,14]]},"reference":[{"key":"2103_CR1","volume-title":"Atlas of clinical hematology","author":"BD Cheson","year":"2008","unstructured":"Cheson BD, Coiffier B (2008) Non-Hodgkin lymphoma. In: Armitage JO (ed) Atlas of clinical hematology, 2nd edn. Current Medicine Group, Philadelphia","edition":"2"},{"issue":"4","key":"2103_CR2","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J et al (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105(4):1417\u20131423","journal-title":"Blood"},{"issue":"10","key":"2103_CR3","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, Hermann S, H\u00e4nel A, Metzner B et al (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104(10):3064\u20133071","journal-title":"Blood"},{"issue":"12","key":"2103_CR4","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12):3725\u20133732","journal-title":"Blood"},{"issue":"1","key":"2103_CR5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","volume":"13","author":"PW Johnson","year":"1995","unstructured":"Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J, Matthews J et al (1995) Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 13(1):140\u2013147","journal-title":"J Clin Oncol"},{"issue":"10","key":"2103_CR6","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH Oers van","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD et al (2006) Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108(10):3295\u20133301","journal-title":"Blood"},{"issue":"9759","key":"2103_CR7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42\u201351","journal-title":"Lancet"},{"issue":"17","key":"2103_CR8","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","volume":"28","author":"MH Oers van","year":"2010","unstructured":"van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M et al (2010) Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28(17):2853\u20132858","journal-title":"J Clin Oncol"},{"issue":"13","key":"2103_CR9","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, B\u00f6ck HP, Repp R, Wandt H et al (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108(13):4003\u20134008","journal-title":"Blood"},{"issue":"29","key":"2103_CR10","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","volume":"28","author":"G Martinelli","year":"2010","unstructured":"Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S et al (2010) Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98. J Clin Oncol 28(29):4480\u20134484","journal-title":"J Clin Oncol"},{"key":"2103_CR11","volume":"2","author":"L Vidal","year":"2009","unstructured":"Vidal L, Gafter-Gvili A, Leibovici L, Shpilberg O (2009) Rituximab as maintenance therapy for patients with follicular lymphoma. Cochrane Database Syst Rev 2, CD006552","journal-title":"Cochrane Database Syst Rev"},{"key":"2103_CR12","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site . Accessed 8 Jan 2014"},{"issue":"6","key":"2103_CR13","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.2005.12.171","volume":"23","author":"LN Gordan","year":"2005","unstructured":"Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW (2005) Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 23(6):1096\u20131102","journal-title":"J Clin Oncol"},{"issue":"12","key":"2103_CR14","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M Ghielmini","year":"2004","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U et al (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule. Blood 103(12):4416\u20134423","journal-title":"Blood"},{"issue":"4","key":"2103_CR15","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244\u20131253","journal-title":"J Clin Oncol"},{"key":"2103_CR16","unstructured":"National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) (2014) Major initiatives, common terminology criteria for adverse events (CTCAE). http:\/\/ctep.cancer.gov\/MajorInitiatives\/Common_Terminology_Criteria.htm . Accessed 8 Jan 2014"},{"issue":"10","key":"2103_CR17","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2006-11-059469","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Donaldson J, Filewich A, Fitzgerald C, Gill KK, Runzer N et al (2007) Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 109(10):4171\u20134173","journal-title":"Blood"},{"issue":"3","key":"2103_CR18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/1078155208100527","volume":"15","author":"A Al Zahrani","year":"2009","unstructured":"Al Zahrani A, Ibrahim N, Al Eid A (2009) Rapid infusion rituximab changing practice for patient care. J Oncol Pharm Pract 15(3):183\u2013186","journal-title":"J Oncol Pharm Pract"}],"updated-by":[{"DOI":"10.1007\/s00277-014-2153-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,7,4]],"date-time":"2014-07-04T00:00:00Z","timestamp":1404432000000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2103-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-014-2103-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2103-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T11:43:22Z","timestamp":1565437402000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-014-2103-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,14]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["2103"],"URL":"https:\/\/doi.org\/10.1007\/s00277-014-2103-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00277-014-2153-6","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,14]]}}}